Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.

ABSTRACT:

Background

Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.

Methods

We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021.

Results

Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2

SUBMITTER: Chemaitelly H 

PROVIDER: S-EPMC8522799 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature